Future potential of Rapid Acceleration of Diagnostics (RADx Tech) in molecular diagnostics - POCTRN
null Future potential of Rapid Acceleration of Diagnostics (RADx Tech) in molecular diagnostics
Future potential of Rapid Acceleration of Diagnostics (RADx Tech) in molecular diagnostics
While necessity is the mother of invention, anomalies have formed the basis for most disruptive discoveries that seed innovations in the sciences.
While necessity is the mother of invention, anomalies have formed the basis for most disruptive discoveries that seed innovations in the sciences. They provide the impetus for paradigm change within a field and reflect differences between observed and theoretically expected data. The coronavirus pandemic was such an anomaly that spawned innovation in the molecular diagnostic testing market and initiated a paradigm change in public health policies, regulatory hurdles, and consumer views of point-of-care (POC) testing. Prior close calls with other viruses, including SARS, MERS, and Ebola, should have prepared the world for the coronavirus pandemic. Yet, many nations, including the United States, found themselves largely unprepared.
RADx: Rapid Acceleration of Diagnostics
In response to the COVID-19 pandemic, the Rapid Acceleration of Diagnostics (RADxsm) initiative was formed to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19.
In the News
Two New Over-the-Counter At-Home COVID-19 Tests Brought to U.S. Market Quickly by Biden-Harris Administration
New HHS actions add to Biden administration efforts to increase access to easy-to-use over-the-counter COVID-19 tests
NIH RADx initiative expands COVID-19 testing innovation for additional types of rapid tests
The need for new test verification and regulatory support for innovative diagnostics
NIH-funded screening study builds case for frequent COVID-19 antigen testing
RADx partnerships speed new COVID testing
Publication reveals essential ingredients of the groundbreaking NIH RADx national diagnostics effort
Innovative COVID-19 Testing RADx Tech Reports Unveiled in Special Issue of IEEE Open Journal of Engineering in Medicine and Biology
Luminostics Announces FDA Authorization and Production Scale-Up of US-Manufactured Smartphone-Based COVID-19 Rapid Test
RADx Expects COVID-19 Portfolio to Accelerate an Era of At-Home Infectious Disease Testing (Login Required)
VIC Foundry, Inc. Receives NIH RADx Funding for Development of an At-home Molecular Diagnostic Test for COVID-19
Ceres Nanosciences Opens Advanced Particle Manufacturing Plant in Northern Virginia to Expand Nanotrap® Particle Manufacturing Capacity for COVID-19 Testing
COVID-19 Testing: Three Breakthrough Solutions in the RADx Initiative
NIH Director: Collaboration Amid Chaos, and Biden’s First 100 Days - How Francis Collins sees the COVID response changing with the new administration
The National Strategy From the COVID-19 Response and Pandemic Preparedness
Winners of HHS Design-a-thon to Develop Innovative Digital Health Tools for COVID-19 At-Anywhere Diagnostic Tests Announced